首页 | 本学科首页   官方微博 | 高级检索  
检索        

表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用
引用本文:李哲,袁守军.表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J].中国临床药理学与治疗学,2004,9(4):361-364.
作者姓名:李哲  袁守军
作者单位:军事医学科学院放射医学研究所药理室,北京,100850
摘    要:表皮生长因子受体 (EGFR)酪氨酸激酶 ,是细胞外信号传递到细胞内的重要枢纽 ,它在信号传导、细胞增殖、分化以及各种调节机制中发挥重要作用 ,在多种癌细胞中过度表达。许多研究表明 ,抑制EGFR酪氨酸激酶活性 ,可抑制肿瘤生长。目前 ,已有几种EGFR酪氨酸激酶抑制剂进入了临床试验。本文对几种EGFR酪氨酸激酶小分子抑制剂在肿瘤治疗中的研究进展做一综述。

关 键 词:表皮生长因子受体  酪氨酸激酶抑制剂  肿瘤治疗  临床试验
文章编号:1009-2501(2004)04-0361-04
修稿时间:2003年11月26

Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
LI Zhe,YUAN Shou-Jun.Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy[J].Chinese Journal of Clinical Pharmacology and Therapeutics,2004,9(4):361-364.
Authors:LI Zhe  YUAN Shou-Jun
Institution:LI Zhe,YUAN Shou-Jun Department of Pharmacology,Institute of Radiation Medicine,Academy of Military Medical Sciences,Beijing 100850,China
Abstract:Epidermal growth factor receptor (EGFR) tyrosine kinase is over-expressed in numerous human tumors, which plays pivotal roles in cellular signal transduction, and it is involved in a variety of tumor cellular behaviors such as proliferation, metastasis, angiogenesis and so on. Many investigations have indicated that tumor growth can be suppressed by inhibiting EGFR tyrosine kinase activity. Currently, several EGFR tyrosine kinase inhibitors are in clinical trial stage.
Keywords:phacology  epidermal growth factor receptor (EGFR)  tyrosine kinase inhibitors  cancer therapy  clinical trial
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号